2Seventy Cuts Jobs As It Streamlines Pipeline, Focuses On Abecma

CEO Nick Leschly Stepping Down, Remaining As Chairman

Nearly two years after its spin-out from bluebird, 2Seventy is slowing in-house R&D and leaning on partners to conserve cash while BMS-partnered Abecma regains its competitive footing.

2seventy Bio, Inc. expected revenue from Abecma (idecabtagene vicleucel) and its $307m in cash as of 30 June to fund its operations into 2026. But with multiple issues impacting sales of its Bristol Myers Squibb Company-partnered product and delays for the T-cell therapy maker’s two clinical-stage programs, 2seventy is restructuring to ensure its cash lasts into at least 2026, with cutbacks that include a 40% workforce reduction, a slowdown in internal R&D and a move to partner more of its programs.

Key Takeaways
  • With Abecma sales set to come in below prior expectations in Q3, 2seventy is cutting jobs and streamlining its R&D pipeline to ensure it has cash at least into 2026.

The restructuring announcement on 12 September comes almost two years after 2seventy was spun out of bluebird bio inc. in...

More from Strategy

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.